Logo

AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer

Share this

AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer

Shots:

  • The P-III CASPIAN study involves assessing of Imfinzi + etoposide + cisplatin/carboplatin or Imfinzi + tremelimumab + CT vs CT as monothx. as a 1L treatment for patients with extensive-stage SCLC across 22 countries including the US & EU
  • The P-III CASPIAN study resulted in meeting its 1EPs i.e- improvement in overall survival in SCLC patients. The safety & tolerability of combination therapy is consistent with the known safety profile
  • Imfinzi is a mAb targeting PD-L1- act by blocking the interaction of PD-L1 with PD-1 and CD80 and is an approved therapy in 45+ countries including the US- EU & Japan based on P-III PACIFIC study for unresectable- Stage III NSCLC

Click here to read full press release/ article

Ref: AstraZeneca | Image: AstraZeneca


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions